Heparin-induced thrombocytopenia
Revision as of 14:42, 9 September 2018 by Benjamintillman (talk | contribs) (→All lines of therapy)
| Section editors | |||
|---|---|---|---|
 |
Shruti Chaturvedi, MBBS, MSCI Baltimore, MD |
 |
Benjamin Tillman, MD Nashville, TN |
0 regimens on this page
0 variants on this page
|
Guidelines
To be completed
All lines of therapy
Argatroban monotherapy
| Study | Evidence | Comparator | Efficacy |
|---|---|---|---|
| Lewis et al. 2001 | Prospective, historical control | Multiple | Reduced all-cause death, all-cause amputation, and new thrombosis |
Anticoagulation
- Argatroban 2 ug/kg/min IV adjusted to maintain activated partial thromboplastin time 1.5 to 3.0 times baseline value.
References
B.E. Lewis, D.E. Wallis, S.D. Berkowitz, W.H. Matthai, J. Fareed, J.M. Walenga, J. Bartholomew, R. Sham, R.G. Lerner, Z.R. Zeigler, P.K. Rustagi, I.K. Jang, S.D. Rifkin, J. Moran, M.J. Hursting, J.G. Kelton, for the ARG-911 Study Investigators. Argatroban anticoagulant therapy in patients with Heparin-induced thrombocytopenia. Circulation. 2001;103:1838-1843. link to original article. PubMed.